Lyell Immunopharma Announces Participation in March Investor Conferences

Core Insights - Lyell Immunopharma, Inc. is a clinical-stage company focused on developing next-generation CAR T-cell therapies for cancer patients [2] Company Overview - Lyell is advancing a pipeline of CAR T-cell therapies targeting both hematologic malignancies and solid tumors [2] - The company employs various technologies to enhance CAR T cells, aiming for durable tumor cytotoxicity and long-lasting clinical responses [2] - Lyell's LyFE Manufacturing Center™ has the capability to manufacture over 1,200 CAR T-cell doses at full capacity, supporting potential commercial launch [2] Upcoming Events - The company will present at the TD Cowen 46 Annual Health Care Conference on March 2, 2026, at 9:10 AM Eastern Time [4] - Lyell will participate in the Leerink Annual Global Healthcare Conference on March 9, 2026, with a fireside chat at 10:00 AM Eastern Time [4] - The company will also be at the Citizens Life Science Conference on March 10, 2026, with a fireside chat scheduled for 11:55 AM Eastern Time [4]